Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

FLUIDDA Presents Novel Imaging Technology for Respiratory Diseases to FDA

Published: Thursday, December 19, 2013
Last Updated: Thursday, December 19, 2013
Bookmark and Share
The FDA hearing is planned for January 17th in Washington DC.

FLUIDDA develops proprietary Functional Respiratory Imaging (FRI) technology that provides a unique entry point into personalized medicine for respiratory diseases.

FRI reduces significantly the number of patients needed in clinical trials, resulting in better drugs coming to the market faster.

FLUIDDA is invited by the FDA to present the benefits of this unique technology for the screening of new respiratory drugs.

Functional Respiratory Imaging (FRI) is FLUIDDA’s proprietary imaging technology with the unique capability of producing highly clinical relevant patient specific biomarkers. These biomarkers present 3D visualization of the patient’s airway and lung geometry, airway resistance and aerosol deposition patterns.

Extensive patient studies demonstrated that FRI has enhanced sensitivity compared to the conventional tests. FRI detects changes in the respiratory system caused by a drug more accurately in fewer patients.

This allows a significant reduction in the number of patients that are needed in clinical trials for people suffering from respiratory diseases such as asthma and COPD (Chronic Obstructive Pulmonary Disease). This implies that better drugs could come to market faster.

FLUIDDA has been invited by the renowned US Food and Drug Administration (FDA) to present the study data concerning their novel biomarker for respiratory diseases. This meeting is a part of the critical path initiative by FDA to endorse the development of new biomarkers to increase the efficiency of drug development.

Jan De Backer, CEO of FLUIDDA, commented: “This invitation is very important for FLUIDDA. Positive feedback from FDA regarding FRI will be a strong signal for pharmaceutical companies to include FRI endpoints in their clinical trials.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!